Vogenx raises $81.3 million in Nasdaq IPO for metabolic disease research

Vogenx, a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, has completed an initial public offering (IPO) on the Nasdaq Capital Market. The company raised approximately $81.3 million by selling 6,250,000 shares of common stock at $13.00 per share, which was the high end of its proposed price range. The stock began trading under the ticker ‘VOGX’ on August 12, 2026.

The capital is intended to support the development of its lead drug candidate, mizagliflozin, which is being tested for post-bariatric hypoglycemia (PBH). PBH is a condition characterized by rapid glucose absorption and dangerous drops in blood sugar following bariatric surgery, for which there are currently no FDA-approved therapies. Mizagliflozin is an oral small molecule designed to inhibit the SGLT1 transporter protein to manage glucose absorption.

Following its debut, Vogenx saw positive market movement, ending its first week of trading at $14.78 per share, a 13% increase from the IPO price.